

(Translated)

Minutes of the Annual General Meeting of Shareholders for the year 2025
of
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

An English version of the minutes of meeting is translated from Thai language. In the event of conflict or difference in interpretation in two languages, the Thai language minutes of meeting shall prevail.

Time and place

The Meeting was held on 22 April 2025 at 10.00 AM by means of electronic meeting (E-AGM) pursuant to the Emergency Decree on Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings via Electronic Means, B.E. 2563 (2020).

Attending Directors for the Meeting (The Company had 11 directors, with 100% attendance)

- | | | |
|-----|-----------------------------------|--|
| 1. | M.D. Thongchai Thavichachart | Chairman of the Board of Directors and Independent Director |
| 2. | Ms. Sopawadee Lertmanaschai | Independent Director, Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee |
| 3. | Pharm. Vinit Usavakidviree | Independent Director and Member of the Audit Committee |
| 4. | Asst. Prof. Lalita Hongratanawong | Independent Director, Member of the Audit Committee and Chairman of the Nomination and Remuneration Committee |
| 5. | Mr. Natthawut Viboonpatanawong | Independent Director and Chairman of the Risk Management Committee |
| 6. | Mr. Tawat Kitkungvan | Director and Member of the Nomination and Remuneration Committee |
| 7. | Mrs. Jintana Suntipisud | Director and Chairman of the Executive Committee |
| 8. | Dr. Sittichai Daengprasert | Director, Member of the Risk Management Committee, Member of the Executive Committee, President (CEO) and Executive Vice President of Business Strategy and Innovation |
| 9. | Mr. Pissanu Daengprasert | Director, Member of the Executive Committee and Executive Vice President of Sales and Marketing |
| 10. | Ms. Jirada Daengprasert | Director, Member of the Nomination and Remuneration Committee, Member of the Executive Committee and Executive Vice President of Finance and Accounting (CFO) |

(Translated)

11. Mr. Sorasit Daengprasert Director, Member of the Risk Management Committee, Member of the Executive Committee and Executive Vice President of Manufacturing and Operations

Attending Management for the Meeting

1. Mr. Kriangkrai Rungruangthaweekul Member of the Executive Committee and Vice President of Finance
2. Ms. Nongnuch Cheawpattayakorn Member of the Executive Committee and Quality Assurance Director
3. Mr. Danaisuan Kunarosombat Member of the Executive Committee and Director of Plant Operations

Attending Auditor from KPMG Phoomchai Audit Ltd. for the Meeting

1. Ms. Kanokorn Phooripanyawanit
2. Ms. Papawadee Sanprom

Preliminaries

Ms. Patcharaphon Puaekbutr welcomed the shareholders to the Annual General Meeting of Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited for the year 2025 (the "Meeting"). She then explained the details of this Meeting that it was a meeting via electronic media, a system having the standard consistent with the conditions and procedures prescribed in the Emergency Decree on Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). In this meeting, the Company used electronic meeting system provided by OJ International Company Limited, which has been certified by Electronic Transactions Development Agency (ETDA). Eligible attendees at the Meeting must complete self-verification in accordance with the methods prescribed by the Company and agree to comply with the requirements for attending the Annual General Meeting of Shareholders for the year 2025. This was to facilitate the shareholders and reduce their travel burden and to make the most of technology.

For the sake of transparency and to comply with the best practices for a shareholders' meeting, the Company invited Ms. Papawadee Sanprom, auditor from KPMG Phoomchai Audit Ltd., to witness the vote counting.

The moderator declared to the Annual General Meeting of Shareholders for the year 2025 of the Company that there were 35 shareholders attending (in person and by proxy), representing an aggregate of

(Translated)

313,984,201 shares, equivalent to 66.16% of the total number of issued shares, and therefore constituting a quorum pursuant to Article 38 of the Company's Articles of Association.

M.D. Thongchai Thavichachart, Chairman of the Board of Directors and Independent Director, who presided as the chairman of the Meeting (the "Chairman"), thanked to the shareholders and opened the Annual General Meeting of Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited for the year 2025. And then he assigned Ms. Patcharaphon Puaekbutr to act as moderator.

Prior to follow meeting agendas, the moderator briefly explained to the shareholders the voting procedure and details of the meeting practice. The voting procedure shall be in accordance with the Company's Articles of Association, i.e., one share carries one vote. Shareholders are able to vote approval, disapproval or abstention in each agenda item. With respect to vote counting, only shareholders' votes in objection and abstention will be counted and then deducted from the total number of votes of the attending shareholders, which results in the remainder being considered approval votes for such agenda item.

The shareholders may cast a vote to "approve", "disapprove" or "abstain" in each agenda item. Once votes have been cast by the shareholders, the system will show a pop up to ask for voting confirmation where the shareholders shall press Agree to confirm their voting. Any shareholder wishing to alter their vote may do so by clicking to vote again. The system will allow one minute of voting per agenda item. Any shareholder failing to press vote in any agenda item shall be deemed to have "approved" in such agenda item.

After casting the vote, the shareholders are asked to return to the E-Meeting window (Zoom) to continue viewing the Meeting audio and video. The staff will gather all votes from the voting system. Voting is unavailable in any agenda item for acknowledgment. Once voting is closed in any agenda item, the shareholders will no longer submit a vote or change the vote in that agenda item.

If any shareholder logs out from the system during the Meeting, the system will exclude the said shareholder's vote in that certain agenda item from the base for calculation to conform with the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). However, the shareholder may log in to attend the Meeting at all times until the Meeting is adjourned.

Furthermore, as the voting procedure for this Meeting is via an online system, void ballots will not occur, except for the case of votes in a proxy form submitted to the Company in advance. Any ballot which (1) is marked in more than one box or (2) does not show true intention of the voter in regard to the voting will be deemed as a void ballot. If any shareholder or proxy delays in attending the Meeting via electronic means, the shareholder or proxy may register and attend the Meeting but will be eligible to vote only in the remaining agenda items. The Company will report to the Meeting details of the voting results for each agenda item after completion of consideration and voting in each agenda item. Nonetheless, if vote counting in certain agenda item takes more time than usual, the Company will proceed with consideration of the following agenda item to enable continuation of the

(Translated)

Meeting, and once the staff have finished vote counting, the voting results will be immediately reported to the Shareholders' Meeting. In addition, the Company recorded this meeting by mean of video.

Prior to cast the vote in each agenda, the Company allows any shareholder who attend the Meeting and wishing to raise questions or provide suggestions related to such agenda, as appropriate, for one minute. The shareholders could do in 2 ways i.e. (a) via chat box and (b) via audio and visual through VDO Conference.

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to propose meeting agendas and nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2025, during 16 September 2024 to 1 November 2024. However, neither meeting agenda nor candidate was proposed and nominated by the shareholders.

Agenda 1 **To Acknowledge the Annual Report for the Year 2024**

The Chairman assigned Dr. Sittichai Daengprasert; President (CEO), to report the Company's performance for the year 2024.

President (CEO) informed the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider the report of the Board of Directors showing the Company's performance in the previous year.

The Board of Directors has already prepared the Directors' Report which described the Company's performance for the year 2024 as detailed in the Annual Registration Form (56-1 One Report) for the year 2024 which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, that Board of Directors had approved and deemed it appropriate to propose the Company's Annual Report for the year 2024 to the Shareholders' Meeting for acknowledgement.

The Company would like to informed the performance related to anti-corruption activities. The Company has determined various charters and policies in order to provide understanding to directors, executives and employees and applied them appropriately. These included good corporate governance, duty and care to stakeholders and anti-corruption. Especially, the Company had anti-corruption policy to express intention and determine guidelines for anti-corruption, also build up good culture in business's operations. The Company expects that such policy will create assurance to stakeholders and regulators. The Company prohibited directors, executives, and employees to participate or involve with all activities that might cast to corruption, both direct and indirect ways. For instance, bribery, give or receive unusual entertainment and/or gift. In addition, the Company set aside

(Translated)

measures over whistleblowing channels, investigations, punishments, protection of whistleblowers and protection to persons who refuse corruption.

In 2024, the Company provided training to directors, executives, and employees in relation to anti-corruption by mean of self-learning through e-learning and all personnels have signed for acknowledgement over the measures. Furthermore, the Company had no claim arose from corruption.

The Company is currently studying information about Thai Private Sector Collective Action Against Corruption and preparing assessment form under Thai Private Sector Collective Action Against Corruption for certifying as member of the collective action.

In overview, the Company presently operates businesses in collaboration to expand groups of customers, which comprised

1. Product research and development, scientific testing in laboratory and training to entrepreneurs.
2. Manufacturing in basis of OEM, Own Brand and Hemodialysis
3. Distributing of goods through traditional shop, TV Shopping and vending machine
4. Providing traditional Thai medical treatment via Suphap Osot Polyclinic

Significant developments in the year 2024 and business plan for 2025

President (CEO) informed the Meeting that the Company had significant development in dietary supplement; namely “Suphap Osot™ Black Sesame and Rice Bran Oil”, by having more marketing communication through LED billboards, sky train and buses, which created good acceptance from customers in 2024. The Company also increased production capacity to create variety of products with high quality to the market.

The Company was awarded “Good” rating from IOD about Corporate Governance for listed companies and “Excellent” rating from TIA about organising AGM.

In 2025, the Company will keep increasing customer groups and launching new products to strengthen brands. Additionally, the Company will conduct process development to enhance resources to aim for sustainably operating results. In addition, the Company keep supporting value added from invested entities.

President (CEO) then gave the shareholders an opportunity to raise questions about the Company's performance for the year 2024.

No shareholder had any question about the Company's performance for the year 2024.

The Meeting acknowledged the Annual Report for the year 2024.

Agenda 2 **To Consider Approving the Financial Statements for the Year Ended 31 December 2024**

The Chairman assigned Ms. Jirada Daengprasert; Executive Vice President of Finance and Accounting (CFO), to report the Company's financial statements for the year ended 31 December 2024.

Executive Vice President of Finance and Accounting (CFO) explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider approving the statement of financial position and statement of comprehensive income at the end of the previous fiscal year, and Article 57 of the Company's Articles of Association and Section 112 of the Public Limited Companies Act, B.E. 2535 (1992), prescribes that the Board of Directors must cause the balance sheet (statement of financial position) and the profit and loss account (statement of comprehensive income) at the end of the Company's fiscal year to be made and propose to the Shareholders' Meeting for consideration and approval in the Annual General Meeting of Shareholders. The Board of Directors must have such the balance sheet and profit and loss account audited by an auditor before proposing them to the Shareholders' Meeting.

The Board of Directors caused the financial statements for the year ended 31 December 2024 and had been audited by the Company's auditor and reviewed by the Audit Committee. The financial statements were presented in the Annual Registration Form (56-1 One Report) for the year 2024 which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, that Board of Directors had approved and deemed it appropriate to propose the financial statements for the year ended 31 December 2024; which have been audited by the auditor and reviewed by the Audit Committee, to the Shareholders' Meeting for approval.

Significant financial information for the year 2024

1. Total revenues from sales and services for the year 2024 was reported at Baht 824.49 million. Whereas, total revenues of the Company for 2023 were Baht 575.58 million. With the 43.2% increased of revenues influenced gross profit margin rose up from 24.9% in 2023 to 37.0% in 2024. For net profit margin, the Company had net profit margin declined from 4.2% to (3.9%) in 2024 resulted from impairment loss of investment in the consolidated financial statements.
2. Financial position: In comparison between 2023 and 2024, the Company had more of current assets. While, shareholders' equity decreased.
3. Cash flows: In 2024, the Company had cash flows from operating activities amounting to Baht 132.12 million which higher than 2023 reported at Baht 40.35 million. Whilst, cash flows from investing activities were Baht 56.64 million for 2024 since acquisition and construction of fixed assets for business expansion have been completed.

(Translated)

Executive Vice President of Finance and Accounting (CFO) gave the shareholders an opportunity to raise questions about the financial statements for the year ended 31 December 2024.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the financial statements for the year ended 31 December 2024 with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	313,984,201	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	313,984,201	100.00000

Agenda 3 To Consider Approving the Omission of Appropriation of Net Profit to be Legal Reserve for the Performance for the Year Ended 31 December 2024 and Omission of Dividend Payment for the Year 2024

The Chairman assigned Dr. Sittichai Daengprasert; President (CEO), to report the appropriation of net profit to be legal reserve for the performance for the year ended 31 December 2024 and omission of the annual dividend payment for the year 2024.

President (CEO) explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider appropriating profits and fund as reserve fund, and Article 52 of the Company's Articles of Association and Section 116 of the Public Limited Companies Act, B.E. 2535 (1992), prescribe that the Company must appropriate part of its annual net profit as a reserve fund in the amount not less than 5% of the annual net profit less accumulated loss brought forward (if any) until this reserve fund reaches the amount not less than 10% of the registered capital.

(Translated)

In addition, Article 49 of the Company's Articles of Association prescribes that dividend payment may not be announced unless it is pursuant to the resolution of the Shareholders' Meeting, and Section 115 of the Public Limited Companies Act, B.E. 2535 (1992), prescribes that dividend payment must be approved by the shareholders' meeting.

The Company has policy to pay dividend at the rate not less than 40% of the net profit according to the Company's separate financial statements after deduction of all reserve funds as stipulated by law and Company's Articles of Association. However, such dividend payment must not exceed the retained profit according to the Company's separate financial statements. In addition, in the case that the Company's financial statements have accumulated deficit, the Company will not consider making dividend payment. The Company may consider paying dividend at the rate lower than the abovementioned rate depending on the Company's performance, financial position and liquidity, as well as the necessity to utilise the working capital for its business operation, the Company's future business expansion plan and other factors relating to the Company's management as deemed appropriate by the Board of Directors.

According to the performance for the year ended 31 December 2024, the Company had net loss and deficit reported in separate financial statements amounting to Baht 34,973,563.09 and Baht 53,464,054.01, respectively. The Board of Directors therefore rendered an approval resolution and deemed it appropriate to propose that the the Shareholders' Meeting consider approving the omission of appropriation of net profit as legal reserve and to omit the annual dividend payment for the year 2024 since the Company had outstanding deficit and net loss in the separate financial statements for the year ended 31 December 2024.

However, interim dividend paid during 2024 amounting to Baht 14,995,741.96 derived from net profit according to separate interim financial statements for the six-month period ended 30 June 2024 which reported net profit and unappropriated retained earnings amounting to Baht 22,874,693.38 and Baht 20,570,830.97, respectively.

President (CEO) gave the shareholders an opportunity to raise questions about the omission of appropriation of net profit as legal reserve for the performance for the year ended 31 December 2024 and omission of the annual dividend payment for the year 2024.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

(Translated)

Resolution: Approved the omission of appropriation of net profit to be the legal reserve, and to omit the annual dividend payment for the year 2024, with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	313,984,201	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	313,984,201	100.00000

Agenda 4 **To Consider Approving Transfer of Legal Reserve and Ordinary Share Premium to Compensate Deficit in the Company's Separate Financial Statements**

The Chairman assigned Dr. Sittichai Daengprasert; President (CEO), to report the transfer of legal reserve and ordinary share premium to compensate deficit in the Company's separate financial statements.

President (CEO) explained to the Meeting that Section 119 of the Public Company Act B.E. 2535 (1992) prescribes that the Company shall able to transfer reserves under Section 51, Section 116 or other reserves to compensate the Company's deficit upon approval from the Shareholders Meeting. The said compensation to deficit must be first from other reserves and then reserve under Section 116 and Section 51, respectively.

According to the Company's separate financial statements for the year ended 31 December 2024 (Audited), the Company had deficit totalled Baht 53,464,054.01. In order to prepare the Company to be ready for dividend payment in the future of the Company has sufficient net profit and cash flows, the Board of Directors considered and deemed appropriate to propose the Shareholders' Meeting to consider approving transfer of legal reserve amounting to Baht 3,861,847.60 and ordinary share premium amounting to Baht 49,602,206.41 to compensate all deficit outstanding. The Company had no other reserves. Following the said transfer of legal reserve and ordinary share premium to compensate deficit, the Company's separate financial statements shall have none of deficit, none of legal reserve, but shall have balance of ordinary share premium amounting to Baht 722,930,059.21. In addition, this compensation shall have no effect to total shareholders' equity of the Company

President (CEO) gave the shareholders an opportunity to raise questions about the transfer of legal reserve and ordinary share premium to compensate deficit in the Company's separate financial statements.

(Translated)

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes, excluding abstentions from the calculation base.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved transfer of legal reserve and ordinary share premium to compensate deficit in the Company's separate financial statements, with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	313,984,201	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	313,984,201	100.00000

Agenda 5 To Consider Approving the Appointment of Directors in Place of Directors who are to be Retired by Rotation

The Chairman explained to the Meeting that, at the Annual General Meeting of Shareholders for the year 2025, there are 3 directors who are to retire by rotation as follows:

- (1) M.D. Thongchai Thavichachart Independent Director
- (2) Mr. Sittichai Daengprasert Director
- (3) Ms. Jirada Daengprasert Director

The Chairman asked directors to retire by rotation to leave from the meeting room. Such directors will attend the Meeting after this agenda has completed. Then, the Chairman asked Asst. Prof Lalita Hongratanawong, the Chairman of the Nomination and Remuneration Committee, to explain to the Meeting agenda.

The Chairman of the Nomination and Remuneration Committee explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider electing the directors in place of directors retiring by rotation, and Article 18 prescribes that, at every Annual General Meeting of Shareholders, at least one-thirds of the directors shall retire from office. If their number

(Translated)

is not a multiple of three, then the number nearest to one-thirds shall retire from office. The directors who have been in office longest shall retire. A retiring director is eligible for re-election.

In this appointment of directors in place of directors retiring by rotation, the Nomination and Remuneration Committee considered it and concluded that the nominated directors were considered in compliance with the Company's nomination procedures, had qualifications in accordance with the related rules and appropriate for the Company's business operation. Additionally, the nomination of director of the Company considers variety in board structure and takes relevant skills as per Board Skill Matrix into account, together with other appropriate qualifications and align with the Company's strategies, both short-run and long-run, without limit to gender, race, religion. The nominated person shall not have prohibited characteristics under the laws and good corporate governance principle for listed companies.

Furthermore, the individuals to be nominated as independent directors had qualifications in accordance with the law on the requirements of independent directors. Profiles of the abovementioned directors are shown in the Detailed Profiles of the Candidates to be Elected as Directors in Place of Directors Retiring by Rotation delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 2).

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2025, during 16 September to 1 November 2024. However, no candidate was nominated by the shareholders.

The Board of Directors, excluding of directors who had interest, was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting consider approving the re-appointment of the retiring directors for another term.

The Chairman of the Nomination and Remuneration Committee gave the shareholders an opportunity to raise questions about the appointment of directors to replace those retiring by rotation.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator informed the Meeting that there is one new shareholder attend the Meeting and that currently the Meeting has 36 shareholders attended the Meeting in total with total number of shares of 314,007,801 shares.

Subsequently, the moderator clarified to the Meeting the voting method for this agenda item. The election will be conducted on individual basis. After that, the moderator reported the resolution as follow.

(Translated)

Resolution: Approved the appointment of the directors who were to be retired by rotation as follows.

- (1) Approved the appointment of M.D. Thongchai Thavichachart to resume the Independent Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

- (2) Approved the appointment of Dr. Sittichai Daengprasert to resume the Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

- (3) Approved the appointment of Ms. Jirada Daengprasert to resume the Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

The said appointed directors returned to the meeting room.

(Translated)

Agenda 6 **To Consider Approving the Determination of Remuneration of Directors and Subcommittees for the Year 2025**

The Chairman asked Asst. Prof Lalita Hongratanawong, the Chairman of the Nomination and Remuneration Committee, to explain the determination of remuneration of directors and subcommittees for the year 2025.

The Chairman of the Nomination and Remuneration Committee explained to the Meeting that under Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider determining the remuneration of directors, and Article 34 prescribes that the reward and remuneration of directors shall be fixed by the Shareholders' Meeting. Accordingly, it was deemed appropriate to propose that the Shareholders' Meeting consider approving the determination of remuneration of directors and subcommittees for the year 2025, as detailed below.

(Unit: Baht)	Types of Directors	Meeting Allowances	
		Per Time	Per Quarter
	Chairman of the Board of Directors	40,000	15,000
	Director and Independent Director	15,000	-
	Chairman of the Audit Committee	30,000	10,000
	Member of the Audit Committee	15,000	-
	Chairman of the Risk Management Committee	12,000	-
	Member of the Risk Management Committee	10,000	-
	Chairman of the Nomination and Remuneration Committee	12,000	-
	Member of the Nomination and Remuneration Committee	10,000	-

Remarks:

1. The directors' remuneration above does not apply to directors who are the Company's executives which receive monthly remuneration.
2. The Company is entitled to additionally pay the directors' remuneration as per the Company's annual turnover. The total directors' remuneration shall not exceed 0.25% of the total revenue as per the Company's annual consolidated financial statements.
3. There is neither other remunerations nor other benefits paid to the directors

The Company had criteria and procedures to determine directors' remuneration as follow:

- (1) Consider thoroughly and filtered base on appropriateness
- (2) Compare with reference to average directors' remuneration in similar industry
- (3) Consider the Company's business and profit growth
- (4) Economic conditions
- (5) Current number of the Company's directors

(Translated)

The Board of Directors was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting for consideration and approval of the determination of remuneration of directors and subcommittees for the year 2025 as proposed.

The Chairman of the Nomination and Remuneration Committee gave the shareholders an opportunity to raise questions about the determination of remuneration of directors and subcommittees for the year 2025.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution shall be passed by votes of no less than two-thirds of the total number of votes of the shareholders attending the Meeting.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the determination of remuneration of directors and subcommittees for the year 2025 as proposed, with the unanimous vote of all votes of the shareholders who attended the Meeting, as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

Agenda 7 To Consider Approving the Appointment of Company's Auditors and Specification of Auditors' Remuneration for the Year 2025

The Chairman asked Ms. Sopawadee Lertmanaschai, the Chairman of the Audit Committee, to explain the appointment of Company's auditors and specification of auditors' remuneration for the year 2025.

The Chairman of the Audit Committee explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider and appoint an auditor and determine the auditor's remuneration; Article 60 prescribes that the Annual General Meeting of

(Translated)

Shareholders must appoint an auditor every year and may re-elect any such retired auditor to resume their position, and Article 61 prescribes that the Annual General Meeting of Shareholders must determine the auditor's remuneration. Therefore, it was deemed appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and specification of auditor's remuneration for the year 2025.

The Audit Committee had considered the appointment of auditor and specification of auditor's remuneration for the year 2025 by taking into account the auditor's experience, performance quality in the previous year and comparing with other audit firms. As a result, the Audit Committee nominated KPMG Phoomchai Audit Ltd. as the Company's auditor with details below.

- (1) Miss Kanokon Phooripanyawanit Certified Public Accountant No. 10512, or
- (2) Miss Nadsasin Wattanapaisal Certified Public Accountant No. 10767, or
- (3) Miss Sukanya Rodkroh Certified Public Accountant No. 12089,

In case of the said auditors were unable to perform the works, KPMG Phoomchai Audit Ltd. will provide other auditors from the same company who have the qualifications and do not have prohibited characteristics as prescribed by law, to audit and certify the Company's financial statements. The Audit Committee specified the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31 December 2025 in the amount not exceeding Baht 2,650,000 (excluding out of pocket expenses and VAT (if any)). Detailed of auditor's remuneration was illustrated in the Annual Registration Form (56-1 One Report) for the year 2024, Topic "Auditor and its affiliates' remuneration" which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). Profiles and experiences of the abovementioned auditors are shown in the Detailed Profiles and Experiences of Auditors for the Year 2025 as delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 3).

All of the Company's subsidiaries use the same audit office to audit and certify the financial statements. The Board of Directors will oversight to ensure that the subsidiaries will prepare financial statements in a timely manner. In addition, the said auditors and audit office do not have any relationship and/or interest with the Company, subsidiaries, executives, major shareholders or related persons thereof.

The Board of Directors was in favor of the Audit Committee's proposal, and therefore, resolved to approve and deemed it appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and the specification of auditor's remuneration for the year 2025 as proposed.

The Chairman of the Audit Committee gave the shareholders an opportunity to raise questions about the appointment of Company's auditors and specification of auditors' remuneration for the year 2025.

(Translated)

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the appointment of (1) Miss Kanokon Phooriphanyawanit, Certified Public Accountant No. 10512, or (2) Miss Nadsasin Wattanapaisal, Certified Public Accountant No. 10767, or (3) Miss Sukanya Rodkroh Certified Public Accountant No. 12089, from KPMG Phoomchai Audit Ltd., or other auditors from the same company, which have qualifications and do not have characteristics as restricted by the laws, to audit and certify the Company's financial statements, and specify the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31 December 2025 in the amount not exceeding Baht 2,650,000 (excluding out of pocket expenses and VAT (if any)), with the unanimous vote of the shareholders who attended the Meeting and cast their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

Agenda 8 To Consider Approving the Additional Amendment of the Company's Objectives No. 31 - 37 and Additional Amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives)

The Chairman asked Dr. Sittichai Daengprasert, President (CEO), to explain the additional amendment of the Company's objectives no. 31 - 37 and additional amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives).

President (CEO) explained to the Meeting that in order to support with the future businesses of the Company, it is deemed appropriate to propose the Shareholders' Meeting to consider approving additional

(Translated)

objectives of the Company no. 31 - 37 and additional amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives) in accordance with Section 31 of the Public Company Act B.E. 2535 (1992) as detailed below:

The Company's objectives no. 31 - 37 added

No. 31 Operate business in relation to private hospital, hospital, polyclinic, Thai traditional medical clinic, applied Thai medical clinic, midwifery and nursing clinic, Chinese traditional medical clinic, medical clinic, dialysis clinic, physical therapy clinic, healthcare clinic, wellness center, healthcare support centre, health treatment and rehabilitation centre, recovery and care centre, nursing home, examine and cure patients, physical therapy planning and caring, training operator in medical and hygiene, together with provide consultancy in relation to medical, hygiene and referral of patients.

No. 32 Operate business in relation to health, beauty, plastic surgery, anti-aging medicine, health and body recovery, health and body therapy. Also, provide administration of business of health, beauty, plastic surgery, anti-aging medicine, health and body recovery, health and body therapy, together with provide consultancy services related to those matters, clinical study, medical experiment for develop and evaluate efficiency, safety and quality of medical product, medicine, vaccine, dietary supplement, medical tool and healthcare product, together with provide services related to clinical study in accordance with global standards and regulations from regulatory agencies.

No. 33 Operate business in relation to manufacture by planting, manufacture without planting, import, export, trade and possess of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and other objects or substances in leaves of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms for medical purposes, academic, research or plant breeding, producing of certified seed and other benefits in commercial or industrial purposes (when permitted by related agencies and received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health, and the operations will be aligned with related laws).

No. 34 Operate domestic or abroad business in relation to import, export, purchase and/or trade of seed, certified seed, young plant, fresh trunk, fresh leaf, dried leaf, inflorescences, or other components of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms, extract substance (including residue) from extraction of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms (when permitted by related agencies and received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health, and the operations will be aligned with related laws).

No. 35 Operate domestic or abroad business in relation to extraction factory, processing factory, import, export and/or trade of product derives from manufacturing, extraction, transforming of Cannabis, Hemp,

(Translated)

Kratom, Opium (e.g. raw rubber, Morphine extract and Codeine), Herbs, Psilocybe mushroom (e.g. dried mushroom, grind power mushroom, capsule, fresh leaf, dried leaf, young plant, extract) and/or other plants or mushrooms in the same genus as the aforementioned plants and mushrooms (when received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health the operations will be aligned with related laws).

No. 36 Operate domestic or abroad business in relation to provide consultancy about manufacturing, import, export of Cannabis, Hemp, Kratom, herb and/or other plants in the same genus as the aforementioned plants (the operations will be aligned with related laws).

No. 37 Invest by holding shares or being partner or participate in project to study, analyse, research or plant breeding, seed production in conjunction with juristic person, fund, organisation or other agencies operate in private or public sectors. Or, being a member of community enterprise registered under the laws and/or agricultural cooperation registered under the laws which operate under coordination and supervision by government agencies for activities about Cannabis, Hemp, Kratom, herb and/or other plants in the same genus as the aforementioned plants (the operations will be aligned with related laws).

Memorandum of Association No. 3 (Objectives) additional amendment

Previously

No. 3 There are 30 objectives of the company

Revised

No. 3 There are 37 objectives of the company

In this regard, the authorities for the registration of additional amendment of the Company's objectives and additional amendment of the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce, shall be assigned to the Company's authorised directors or the persons assigned by the Company's authorised directors to register in aforementioned matters. In addition, such persons shall have authority to amend and add wordings to be in compliance with the order of the Registrar in order to complete the registration.

President (CEO) gave the shareholders an opportunity to raise questions about the additional amendment of the Company's objectives no. 31 - 37 and additional amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives).

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution shall be passed by votes of no less than three-fourths of the Shareholders who attend the meeting and eligible to vote.

The moderator explained the voting method and then reported the resolution as follow.

(Translated)

Resolution: Approved the additional amendment of the Company's objectives no. 31 - 37 and additional amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives) with the unanimous vote of the shareholders who attended the Meeting and cast their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	314,007,801	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	314,007,801	100.00000

Agenda 9 **Other Business (if any)**

The Chairman gave the shareholders an opportunity to raise questions or propose agenda items other than those shown in the agenda.

No shareholder raised any question or proposed any other agenda item. The Chairman therefore thanked the shareholders, directors, executives and other team members and declared the Meeting closed.

The Meeting adjourned at 11.30 AM.

(M.D. Thongchai Thavichachart)

Chairman of the Meeting

(Ms. Jirada Daengprasert)

Company Secretary